

# Analytical Methods

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

---

1  
2  
3 **1 Novel artificial antigen synthesis for antibody production and development of an**  
4 **2 indirect competitive ELISA of cyanocobalamin**

5  
6  
7 3 Fanfan Yang, Lixin Zhu, Wei Meng, Renrong Liu✉

8  
9 4 School of Life Science, Jiangxi Science & Technology Normal University, Jiangxi, Nanchang,  
10 5 330013, China

11  
12 6 ✉ **Corresponding author:** Renrong Liu, Ph.D

13  
14 7 School of Life Science, Jiangxi Science & Technology Normal University, Jiangxi, Nanchang,

15  
16 8 330013, China.

17  
18 9 Tel: +86-0791-88539360

19  
20 10 Fax: +86-0791-83815794

21  
22 11 Email: lilirenrong@hotmail.com

23  
24  
25  
26  
27 12

28  
29 13

30 14

31 15

32 16

33 17

34 18

35 19

36 20

37 21

38 22

39 23

40 24

41 25

42 26

43 27

44 28

45 29

46 30

47 31

48 32

49 33

50 34

51 35

52  
53  
54  
55  
56  
57  
58  
59  
60

---


**Abstract:**

In the current work, cyanocobalamin was coupled to Bovine Serum Albumin (BSA) and ovalbumin (OVA) by CDI method to produce artificial antigens. Then a monoclonal antibody (MAB) against cyanocobalamin was acquired. In comparison with other reported antibodies, the MAB showed good specificity toward cyanocobalamin. Cross reactivity was found to be less than 0.01% with other compounds of vitamin B, except for three analogs of cobalamins which indicated from 0.27% to 2.31%. An indirect competitive enzyme-linked immunosorbent assay (ic-ELISA) for the detection of cyanocobalamin was developed based on the MAB. Under the optimum conditions, the limit of detection was  $0.2 \text{ ng mL}^{-1}$  with a linear working range of 2–100  $\text{ng mL}^{-1}$  ( $R^2=0.993$ ). The spiked samples were detected with recovery ranging from 86.02–110.54%, and the coefficients of variation were from 2.62% to 13.7%. Six commercially available vitamin supplements were tested by ELISA method, after purification with immunoaffinity column, the samples were validated by HPLC with UV detection at 361 nm. The results obtained also showed good correlation between ELISA and HPLC ( $R^2=0.998$ ). Thus, the method proposed had been proved to be a trustworthy tool to quantify cyanocobalamin in  $\text{vB}_{12}$  tablets supplements.

**Keywords:** cyanocobalamin, ELISA, immunoaffinity column, HPLC

**1. Introduction**

The  $\text{B}_{12}$  vitamins, or cobalamins, are some organic complex containing central cobalt ion in a corrin ring.<sup>1</sup> Cobalamins consist of four major forms which were cyanocobalamin, adenosylcobalamin, hydroxocobalamin and methylcobalamin respectively (Fig. 1).<sup>2, 3</sup> As an essential nutrient for human health,  $\text{B}_{12}$  vitamins play an important role in the synthesis of DNA and development of the myelin sheath, especially in blood delivery system and nervous system, deficiency of  $\text{B}_{12}$  vitamins may lead to pernicious anemia or irreversible neurological damage.<sup>4, 5</sup> However, excessive intake of  $\text{B}_{12}$  vitamins may cause allergic reaction or anaphylactic shock.<sup>6</sup> Besides, they are such vitamins that have great influences on human health at the nanogram level, and a moderate consumption of  $\text{B}_{12}$  vitamins is crucial in acceptable daily intake.<sup>7-9</sup>



**Fig. 1** The structures of cyanocobalamin, methylcobalamin, hydroxocobalamin and adenosylcobalamin respectively

Mostly, B<sub>12</sub> vitamins are found in animal foods including meat, milk and eggs products but practically free from plant foods. In other words, B<sub>12</sub> vitamins deficiency more inclined to vegetarians or some older people who was unable to absorb naturally occurring B<sub>12</sub> vitamins. In order to avoid suffering B<sub>12</sub> vitamins deficiency, the B<sub>12</sub> vitamin supplements or fortified foods were suggested to be taken to meet their requirements. One B<sub>12</sub> vitamin that was widely added to foods or vitamin tablets is cyanocobalamin, which with a salient characteristic of higher stability than other cobalamins, so cyanocobalamin is well-known as vB<sub>12</sub>.<sup>10</sup> Actually, owing to the high-price and easy-decomposition of vB<sub>12</sub> during processing and storage, only a low level of vB<sub>12</sub> was exist in the products, and vB<sub>12</sub> deficiency was unavoidable even they had taken them.<sup>11</sup> Thus, a rapid and accurate method for the determination of vB<sub>12</sub> in varies vitamin supplements should be set up imminently.

Although many traditional analytical methods had been employed in detecting vB<sub>12</sub>, such as high-performance liquid chromatography (HPLC), liquid chromatography-mass spectrometry (LC-MS),<sup>12-15</sup> biosensor method,<sup>16</sup> spectrophotometry or fluorescence assay,<sup>17, 18</sup> they could hardly avoid complex samples pretreatment procedure and matrix effects, coupling with the expensive instruments make them difficult to popularize. Microbiological assay (MBA) was used as a dominant detection method by many countries which showed highly sensitive,<sup>19-21</sup> however, time-consuming, demanding specialized technical input and low precision limited the development of its use. Furthermore, the enzyme linked immunosorbent assay (ELISA) is a rapid method with the characteristics of accuracy, specificity, efficiency and almost free of matrix effects in miscellaneous samples.<sup>9, 22</sup> In this study, the MAB specifically against vB<sub>12</sub> was obtained. After a full optimization procedure, the ic-ELISA for detecting vB<sub>12</sub> was established and sample

1 detection results were confirmed by IAC-HPLC method. The results showed good correlation  
2 between ELISA and IAC-HPLC method, it also revealed that the ic-ELISA method is a promising  
3 tool for vB<sub>12</sub> detection.

## 4 **2. Experimental**

### 5 **2.1 Materials and reagents**

6 Cyanocobalamin (vB<sub>12</sub>), Vitamin B<sub>1</sub>, B<sub>2</sub>, B<sub>5</sub>, B<sub>6</sub>, B<sub>8</sub>, Bovine serum albumin (BSA), N, N'  
7 -carbonyldiimidazole (CDI), Ovalbumin (OVA), 3,3',5,5'-tetramethylbenzidine (TMB) and goat  
8 anti-mouse IgG-HRP, Freund's complete adjuvant (FCA) and Freund's incomplete adjuvant (FIC)  
9 were all purchased from Sigma Chemical Co., Ltd (USA). Methylcobalamin, Hydroxocobalamin  
10 and Adenosylcobalamin were obtained from Wuhan Dahua Pharmaceutical Co., Ltd (China).  
11 Dimethyl sulfoxide (DMSO), Ethanol (CH<sub>3</sub>CH<sub>2</sub>OH) and Trifluoroacetic acid (CF<sub>3</sub>COOH) were  
12 obtained from Damao Chemical Reagent Co., Ltd. (Tianjin, China). Acetonitrile (CH<sub>3</sub>CN) for  
13 HPLC use was obtained from Tedia company (USA). All other chemicals involved were of  
14 analytical reagent grade. immunoaffinity column was made in our lab Microwell plates and  
15 Millipore Millex-GP (22 μm) were purchased from COSTAR Co., Ltd (USA) and Merck  
16 Millipore Ltd (Germany). Vitamin B<sub>12</sub> samples were purchased from a large supermarket.

### 17 **2.2 Instruments**

18 Microplate Reader (MKS) used for ELISA was obtained from Thermo Co., Ltd (ShangHai),  
19 UV-VIS spectrophotometer was model 2600 and obtained from Shanghai Analytical Instrument,  
20 Agilent HPLC 1100 accompanied with Agilent ZORBAX Eclipse Plus C18 (4.6\*150 mm, 3.5 μm  
21 particle size) column used for samples analysis was purchased from Agilent Co., Ltd (USA).  
22 High-speed centrifuge used was an Eppendorf 5804 R instrument (Germany).

### 23 **2.3 Buffers and solutions**


24 Phosphate-buffered saline (PBS pH 7.4) was prepared by dissolving 2.9 g of Na<sub>2</sub>HPO<sub>4</sub>, 8.0 g  
25 of NaCl, 0.2 g of KCl and 0.2 g of KH<sub>2</sub>PO<sub>4</sub> in 1000 mL of Distilled water, PBS with 0.05%

1 Tween-20 (PBST). Block solution was prepared by dissolving 5 g of skimmed milk in 100 mL  
2 distilled water.

3 All experiments were performed in compliance with administration of affairs concerning  
4 experimental animals approved by the State Council on October 31, 1988 in China and laboratory  
5 animal ethics review committee of Jiangxi province.

#### 6 2.4 Preparation of the complete antigen

7 VB<sub>12</sub> was conjugated to BSA and OVA by CDI (N, N'-carbonyldiimidazole) method. CDI  
8 was used to activate the hydroxyl of vB<sub>12</sub> and then conjugated to a carrier protein (Fig. 2). Briefly,  
9 2.3 mg of vB<sub>12</sub> and 3.6 mg of CDI were dissolved in 250 μL anhydrous DMSO in a 5 mL vial and  
10 carried out the activation reaction at 30°C for 3h under continuous stirring in the dark. The  
11 obtained solution was added slowly to a BSA solution (6 mg BSA dissolved in 1.3 mL PBS, pH  
12 7.4), then stirred for 18h at 30°C in the dark and the obtained solution (vB<sub>12</sub>-BSA) was dialyzed  
13 against distilled water at 4°C for 3 days (2 changes per day). Similarly, vB<sub>12</sub>-OVA was treated as  
14 described above. For identifying the complete antigens, both of the conjugates were scanned  
15 respectively by a UV spectrophotometer, finally the conjugates were freeze-dried and stored at  
16 -20°C until further use.



19 **Fig. 2** Synthesis of vB<sub>12</sub> artificial antigen

#### 20 2.5 Production of monoclonal antibody against vB<sub>12</sub>

21 The immunogens (vB<sub>12</sub>-BSA) synthesized by CDI method were used to produce MAB. For  
the primary immunization, vB<sub>12</sub>-BSA was emulsified with isopyknic Freund's complete adjuvant,

1 then six Balb/c female mice (8–10 weeks old) were immunized with BSA-vB<sub>12</sub> (60 µg protein per  
2 mice) subcutaneously at multiple sites (10–15 sites). Three weeks later, the immunization was  
3 boosted with vB<sub>12</sub>-BSA emulsified with Freund's incomplete adjuvant, another booster  
4 immunization were performed at a 3 week interval. The titer of antiserum was determined by  
5 ic-ELISA, in which the vB<sub>12</sub>-OVA was used as coating antigen. After four boosters, one of the  
6 mice exhibited the highest titer, then it was immunized with 30 µg of BSA-vB<sub>12</sub> through the tail  
7 veins as a final dose for fusion experiment. 3 days later the mouse was sacrificed for spleens and  
8 the splenocytes was fused with the SP2/0 myeloma cells by hybridoma technique. Finally the  
9 hybridomas were selected in a HAT medium and cultured in 96-well plates, culture supernatants  
10 from each well were detected by ic-ELISA with the aim of screening the positive hybridomas  
11 which could produce antibodies specific to vB<sub>12</sub>.

## 12 2.6 Titration of MAB

13 The checkerboard procedure was performed in order to determine the optimal dilution of  
14 coating antigen and antibody by ic-ELISA. In short, microplates were coated with 110 µL of  
15 vB<sub>12</sub>-BSA at various concentrations (0.5, 1, 2, 4 µg mL<sup>-1</sup>) in PBS at 37°C for 2 h in the dark, after 3  
16 times' washing with PBST solution, 320 µL per well of 5% skimmed milk were added as the  
17 blocking solution for 2 h incubation at 37°C, MAB from hybridoma cell culture supernatant was  
18 diluted in a series of standards (1:100, 1:200, 1:400, 1:800, 1:1600, 1:3200, 1:6400) with PBS and  
19 added to the corresponding plates for 40 min at 37°C, after washing 3 times with PBST solution,  
20 100 µL of IgG-HRP was diluted at 1:2500 and added to each well for 40 min, 100 µL of TMB  
21 solution was added to the plates and incubated for 8 min, then stop the reaction by using 2 mol L<sup>-1</sup>  
22 H<sub>2</sub>SO<sub>4</sub> (50 µL per well) and recorded the absorbance at 450 nm.

## 23 2.7 ELISA Procedures

24 Ic-ELISA procedure was carried out as mentioned below. The plates were coated with 110 µL  
25 of vB<sub>12</sub>-BSA in PBS at 37°C for 2 h in the dark, after 3 times' washing with PBST solution, 320 µL  
26 of 5% skimmed milk were added to per well for 2 hours' incubation and then washed with PBS-T  
27 solution, 50 µL of the optimized concentration of MAB and 50 µL of a serial concentrations of

1  
2  
3 1 vB<sub>12</sub> standard solutions or samples were added to each well for 40 min at 37°. The plates were  
4  
5 2 washed with PBST solution, incubated for 40 min with 100 µL of IgG-HRP, washed and dried.  
6  
7 3 TMB was added for 8 min (100 µL per well) and stopped the reaction by 50 µL of 2 mol L<sup>-1</sup>  
8  
9 4 H<sub>2</sub>SO<sub>4</sub>, and finally measured at 450 nm.

## 5 **2.8 Standard Addition**

### 6 **2.8.1 Samples Preparation**

7 The vitamin supplement samples for spike experiment were purchased in supermarket and  
8 proved to be free of vB<sub>12</sub>. 10 tablets were exactly weighed and ground by mortar to a uniform  
9 powder, then the average weight of one tablet was weighted and transferred into a brown flask. 50  
10 mL distilled water was added and spiked at three different concentrations (1, 2 and 4 µg slice<sup>-1</sup>)  
11 with vB<sub>12</sub>, and the content was sonicated at 42° in the dark. After 30 min' incubation, it was  
12 transferred to a volumetric flask and adjusted to the 100 mL volume by distilled water (the  
13 concentrations of vB<sub>12</sub> were 10, 20 and 40 ng mL<sup>-1</sup>). The solution was mixed well and centrifuged  
14 at 10000 rpm for 15 min, and then the supernatant was transferred into 50 mL tube in the dark.

### 15 **2.8.2 For ELISA analysis and HPLC analysis**

16 The samples solution obtained above were detected directly by ic-ELISA. However, for  
17 HPLC, the solution should be processed to avoid suffering from matrix effects. For this reason, the  
18 immunoaffinity column for vB<sub>12</sub> was applied to purify and concentrate the sample extracts. Briefly,  
19 1 mL of obtained samples solution with different concentrations were dissolved in 20 mL distilled  
20 water for clean-up by immunoaffinity column (let the solution drain by gravity at room  
21 temperature). After 2 times' washing with 10 mL distilled water, 3 mL methanol was used to elute  
22 antigen (vB<sub>12</sub>) into a 10 mL glass tube, and evaporate eluate completely by water-bath at 65°. 1  
23 mL ultra pure water was added to the each tube, shaken and filtered through a 0.45 µm filter, then  
24 100 µL solution was injected into chromatography with the operation conditions as below (Table  
25 1).<sup>23,24</sup>




**Table 1** Chromatographic conditions for gradient elution of vB<sub>12</sub>. Mobile phase A consisted of 0.025% (CF<sub>3</sub>COOH) in doubly distilled water, mobile phase B was acetonitrile absolutely, flow rate was 1 mL min<sup>-1</sup> with running time of 30 min at 25 °C.

Time/min	Mobile phase A (%)	Mobile phase B (%)
0–3.5	100	0
3.5–11	75	25
11–19	65	35
19–20	90	10
20–30	100	0

### 3 Result and Discussion

#### 3.1 Characterization of vB<sub>12</sub> conjugates


The UV spectrum were recorded from 200 nm to 400 nm, from the scanning diagram, the characterization absorption peaks of vB<sub>12</sub> and BSA were exhibited at 361 nm and 278 nm respectively. However, the absorption peaks of vB<sub>12</sub> conjugates not only contained the characteristic absorption peaks at 361 nm (vB<sub>12</sub>), but also had the absorption peaks at 278 nm (BSA), which suggested the vB<sub>12</sub>-BSA conjugates were successfully synthesized (Fig. 3). Similarly, the vB<sub>12</sub>-OVA conjugates were also proved to be synthesized successfully.



**Fig. 3** UV absorption spectra of vB<sub>12</sub>, BSA, and vB<sub>12</sub>-BSA

#### 3.2 Monoclonal antibody titer


1 According to expectation, fusion experiment was performed and the specific MAB was  
 2 obtained successfully, the subclass of MAB was  $\kappa$  IgG2a and the titer of antibody was determined  
 3 by checkerboard method (Fig 4). The diagram indicated that  $1 \mu\text{g mL}^{-1}$  of the antigen and the  
 4 antibody titer of 1:3200 was the best concentrations in ELISA respectively.



5  
6 **Fig. 4** Checkerboard curve of antigen-antibody of vB<sub>12</sub>

### 7 3.3 Optimization of ELISA conditions


8 As vB<sub>12</sub> was easily dissolved in water or ethanol and decomposed in strong acid or alkali,  
 9 several influence factors such as pH, alcohol and ionic strength to ELISA were examined, each  
 10 condition were performed 4 times and then the half inhibition concentration (IC<sub>50</sub>) of different  
 11 conditions were obtained. Besides, B<sub>0</sub>/IC<sub>50</sub> usually as an important factor to judge the performance  
 12 of ELISA, higher ratio means higher sensitivity.<sup>25, 26</sup> As shown in Fig 5, when the pH was 6.5,  
 13 B<sub>0</sub>/IC<sub>50</sub> value was the highest (0.097), and the IC<sub>50</sub> reduced to the minimum ( $10.51 \text{ ng mL}^{-1}$ ). The  
 14 existence of ethanol could inhibit the interaction between antibody and antigen (Fig. 6). The IC<sub>50</sub>  
 15 increased gradually when the concentration of ethanal increased from 0 to 30%, and the higher  
 16 concentration of ethanol, the higher value of IC<sub>50</sub>. For ionic strength (Fig. 7), the highest B<sub>0</sub>/IC<sub>50</sub>  
 17 value (0.090) was obtained when the salt concentration was around  $100 \text{ mmol L}^{-1}$ , the IC<sub>50</sub> was  
 18  $13.3 \text{ ng mL}^{-1}$ , however, water solution (pH 6.5) seemed to be the most sensitive. So water solution  
 19 at pH value of 6.5 was chosen as the optimal conditions. Under the optimum conditions the  
 20 dose-response curve was obtained (Fig. 8), the limit of detection (IC<sub>10</sub>) was  $0.2 \text{ ng mL}^{-1}$ , and the  
 21 linear range was from  $2 \text{ ng mL}^{-1}$  to  $100 \text{ ng mL}^{-1}$ .



1

2


**Fig. 5** Effects of pH on ELISA



3

4

**Fig. 6** Effects of ethanol concentration on ELISA




5

6

**Fig. 7** Effects of ion concentration on ELISA

7

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Figure. 8** The competitive inhibition curve and calibration curves in the linear range (inset) for vB<sub>12</sub>

### 3.4 Cross-reactivity and sensitivity

As described above, vB<sub>12</sub> (cyanocobalamin) is more similar to its related compounds in structure (Fig 1), which could lead to high cross reactivity. Thus, with the aim of testing the specificity of MAB, the cross reactivity of vB<sub>12</sub> was measured by ic-ELISA. As the data shown in Table 2, the cross reactions of the other three compounds were all lower than 3%, hydroxocobalamin revealed little high cross-reactivity of only 2.31%, methylcobalamin, adenosylcobalamin showed the cross-reactivity of 0.53% and 0.27% respectively. No cross reactivity was detected with other related vitamin B compounds, which showed the MAB was highly specific against cyanocobalamin.

**Table 2** Cross-reactivity of various of vitamin B compounds (n=4)

<i>Forms of vitamin B</i>	<i>50%B/B<sub>0</sub> (ng ml<sup>-1</sup>)</i>	<i>Cross reactivity (%)</i>
Cyanocobalamin	10.51	100
Methylcobalamin	1975.63	0.53
Hydroxocobalamin	446.60	2.31
Adenosylcobalamin	3948.51	0.27
Vitamin B <sub>1</sub>	NR	<0.01
Vitamin B <sub>2</sub>	NR	<0.01
Vitamin B <sub>5</sub>	NR	<0.01
Vitamin B <sub>6</sub>	NR	<0.01
Vitamin B <sub>8</sub>	NR	<0.01

NR: no response

### 3.5 Preparation of immunoaffinity column

The  $\nu\text{B}_{12}$  monoclonal antibodies obtained were coupled with CNBr-activated sepharose 4 fast flow, then the immunosorbent was treated with ethanolamine buffer (0.1 mol L<sup>-1</sup>, pH 8.0) at room temperature. After 3 hours' incubation, the gel was washed by PBS (0.01 mol L<sup>-1</sup>, pH 7.4) to remove the unreacted antibody. The gel was washed with Tris-HCl buffer (0.1 mol L<sup>-1</sup>, pH 8.0) and sodium acetate buffer (0.1 mol L<sup>-1</sup>, pH 3.6) for three times and stored in PBS containing 0.02% (v/w) sodium azide at 4°C overnight. Finally the gel was washed by 20% ethanol and filled in 1 mL injector for further use.

### 3.6 ELISA Analysis and HPLC Confirmation

ELISA was usually used as a tool of qualitative and half-quantitative determination, so each of the establishment of ELISA method should be confirmed by some more accurate instrument methods.<sup>27</sup> In this work, HPLC method was implemented and  $\nu\text{B}_{12}$  standard addition recoveries experiments were performed to compare with the ELISA method (table 3). As the data shown, good recoveries were obtained from each method. The ELISA method showed recovery rates of 86.02% to 110.54% and CVs of 2.62–13.7%. Meanwhile, the average recoveries of HPLC method ranged from 78.42% to 102.94%, and it showed more credible and accurate than ELISA's with a coefficient of 0.19% to 2.94%. Besides, some results acquired by ELISA method were little higher than the HPLC method's, and this distinction may cause by nonspecific adsorption of reagents used during the ic-ELISA procedure. The data also indicated that the ELISA method for the detection of  $\nu\text{B}_{12}$  was almost free of the matrix effects, and it was more efficient in screening and detecting  $\nu\text{B}_{12}$  samples, which the HPLC method can't attain.

**Table 3** Recoveries of  $\nu\text{B}_{12}$  in Blank Vitamin Samples by ELISA and HPLC. Intra-assay CV was determined by 6 replicates on one day, and inter-assay CV was determined by 4 replicates, once a day.


vB <sub>12</sub>	Fortified (ng mL <sup>-1</sup> )	ELISA				HPLC	
		Intra-assay		Inter-assay		Recovery (%)	CV (%)
		Recovery (%)	CV (%)	Recovery (%)	CV (%)		
Sample 1	10	92.89	10.50	93.53	7.41	102.94	2.94
	20	110.54	7.36	108.2	8.29	93.65	2.18
	40	98.41	2.62	93.65	4.80	88.87	2.47
Sample 2	10	86.02	4.01	90.38	9.37	78.43	2.64
	20	88.32	6.27	93.40	11.06	95.23	2.67
	40	97.90	3.81	94.02	6.36	87.96	0.19
Sample 3	10	92.53	13.7	89.49	10.28	91.47	0.70
	20	102	3.12	104.4	5.61	92.23	2.85
	40	100.4	13.4	96.05	6.52	92.73	2.60

### 3.7 Unknown Samples Detection

Six vB<sub>12</sub> supplements (solid samples) were tested by ELISA and validated by HPLC for further evaluation (Table 4). The consistency was obtained between the two methods ( $R^2=0.998$ , Fig. 9), which indicated the ELISA method offer an accurate approach for detecting vB<sub>12</sub> in real samples. Besides, the results also showed that some of determined values are exactly lower than their labeled values such as sample 5, which was proved to be no content. Nevertheless, most of the commercially available vB<sub>12</sub> supplements were qualified.

**Table 4** unknown samples detection by ELISA and HPLC (n=6).

vB <sub>12</sub> supplements	Labeled ( $\mu\text{g slice}^{-1}$ )	ELISA		HPLC	
		Tested ( $\mu\text{g slice}^{-1}$ )	CV (%)	Tested ( $\mu\text{g slice}^{-1}$ )	CV (%)
Sample 1	1.87	2.72±0.023	7.66	2.22±0.02	1.04
Sample 2	2.51	2.99±0.73	8.15	2.96±0.04	0.12
Sample 3	1	1.09±0.11	9.78	0.98±0.01	0.67
Sample 4	3	3.56±0.09	2.53	2.88±0.01	0.40
Sample 5	1.3	0	0	0	0
Sample 6	25	20.76±2.16	10.41	22.2±0.25	1.14



**Fig. 9** Correlation between the ic-ELISA and HPLC methods for authentic samples. The regression equation was  $y = 1.084x - 0.417$ ,  $R^2 = 0.998$

#### Conclusion

VB<sub>12</sub> is a small molecular that can't initiate an immune response itself, so it needs to be coupled with a big carrier such as protein to become a complete antigen.<sup>28</sup> In previous study of vB<sub>12</sub> conjugates, acid hydrolysis procedure was performed to product functional group (carboxyl groups) and then reacted with protein by EDAC method. However, the procedure of acid hydrolysis might destroy the structure of vB<sub>12</sub> if reaction condition was not well controlled,<sup>29</sup> and finally might lead to the low specificity and affinity of acquired antibody. For this reason, the synthesis of vB<sub>12</sub> conjugates in this paper choose the hydroxyl as functional group to coupled with BSA, which could maintain the integrity of vB<sub>12</sub> and product the antibody with high specificity. For L.Sagaya's study the antibody against vB<sub>12</sub> was with the limit of detection (LOD) of 10 ng mL<sup>-1</sup>, and the cross-reactivity of adenosylcobalamin, hydroxocobalamin and methylcobalamin were 32.8%, 14.6% and 27.6%. Whereas the MAB achieved in this approach have higher sensitivity and specificity than L.Sagaya reported before.<sup>9</sup> The average recoveries of vB<sub>12</sub> from vitamin solid samples were from 86.02% to 110.54%, which were satisfactory when compared with HPLC. Thus, as a promising method, it might provide fast and reliable results for the determination of vB<sub>12</sub>.

#### Acknowledgements

This work was financially supported by grants from National Natural Science Foundation of China

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

---

1 (No. 81360429) and Natural Science Foundation of Jiangxi Province (No. 20122BAB214006,  
2 20132BAB214004).

### 3 Reference

- 4 1. D. Hampel, S. Shahab-Ferdows, J. M. Domek, T. Siddiqua, R. Raqib and L. H. Allen, *Food*  
5 *chemistry*, 2014, 153, 60-65.
- 6 2. S. Yamada, K. Yamada, N. Nishikawa, R. Hioki, M. Nirasawa, K. Kii, H. Ryugo, M. Iwama  
7 and M. Fukuda, *Scandinavian Journal of Clinical & Laboratory Investigation*, 2004, 64,  
8 185-194.
- 9 3. N. Akbay and E. Gök, *Journal of Analytical Chemistry*, 2008, 63, 1073-1077.
- 10 4. F. Samari, B. Hemmateenejad, Z. Rezaei and M. Shamsipur, *Analytical Methods*, 2012, 4,  
11 4155.
- 12 5. L. S. Selvakumar and M. S. Thakur, *Analytica chimica acta*, 2012, 722, 107-113.
- 13 6. J. Sun, X. Zhu and M. Wu, *Journal of fluorescence*, 2007, 17, 265-270.
- 14 7. A. J. Nepote, P. C. Damiani and A. C. Olivieri, *Journal of Pharmaceutical and Biomedical*  
15 *Analysis*, 2003, 31, 621-627.
- 16 8. N. Zhang, W. Wang, K. Wang, Z. Ding and Z. Wei, *Spectroscopy Letters*, 2008, 41, 332-336.
- 17 9. L. S. Selva Kumar and M. S. Thakur, *Analytical biochemistry*, 2011, 418, 238-246.
- 18 10. L. S. Selvakumar, K. V. Ragavan, K. S. Abhijith and M. S. Thakur, *Analytical Methods*, 2013,  
19 5, 1806.
- 20 11. F. Watanabe, Y. Yabuta, T. Bito and F. Teng, *Nutrients*, 2014, 6, 1861-1873.
- 21 12. C. J. Blake, *Analytical and bioanalytical chemistry*, 2007, 389, 63-76.
- 22 13. S. R. Koyyalamudi, S. C. Jeong, K. Y. Cho and G. Pang, *Journal of agricultural and food*  
23 *chemistry*, 2009, 57, 6327-6333.
- 24 14. H. Salem, *Chromatographia*, 2010, 72, 327-330.
- 25 15. D. Guggisberg, M. C. Risse and R. Hadorn, *Meat science*, 2012, 90, 279-283.
- 26 16. E. A. S. Crooks, C. E. S. Eriksson, R. F. M. Hallstrom and J. H. H. Indyk, *Journal of AOAC*  
27 *International* 2011, 94, 1217-1226.
- 28 17. H.-B. Li and F. Chen, *Fresenius J Anal Chem*, 2000, 368, 836-838.



- 
- 1  
2  
3 18. J. Medina-Escriche, M. L. Hernandez-Llorens and M. L.-E. a. A. Sevillano-Cabeza, *The*  
4 *Analyst*, 1987, 112, 309-311.  
5  
6  
7 19. B. P. Kelleher and S. D. O. Broin, *J Clin Pathol* 1991, 44, 592-595.  
8  
9 20. S. O'Broin and B. Kelleher, *J Clin Pathol*, 1992, 45, 344-347.  
10  
11 21. M. A. M and S. J. M, *Methods in enzymology*, 1997, 281.  
12  
13  
14 22. C. D. T. Sara, A. Rosario, G. S. Cha and L. G. B. a. M. E. Meyerhoff, *Microchimica Acta*,  
15 1989, 97, 65-73.  
16  
17  
18 23. O. Heudi, T. Kilinc, P. Fontannaz and E. Marley, *Journal of chromatography. A*, 2006, 1101,  
19 63-68.  
20  
21 24. P. Chen, W. R. Wolf, I. Castanheira and A. Sanches-Silva, *Analytical Methods*, 2010, 2, 1171.  
22  
23  
24 25. Z. L. Xu, Y. D. Shen, Y. M. Sun, K. Campbell, Y. X. Tian, S. W. Zhang, H. T. Lei and Y. M.  
25 Jiang, *Talanta*, 2013, 103, 306-313.  
26  
27 26. M. Tang, J. Wei, H. Du, J. Zhang, D. Yang and Y. Peng, *Anal. Methods*, 2015, 7, 3402-3410.  
28  
29  
30 27. Y. Ye, P. Wang, Y. Zhou, F. Chen and X. Wang, *Food Control*, 2011, 22, 1072-1077.  
31  
32 28. C. Ju, Y. Xiong, A. Gao, T. Yang and L. Wang, *Hybridoma*, 2011, 30, 95-100.  
33  
34 29. M. Ying-qing, W. Xia and Z. X.-g. a. L. Li-qiang, *Journal of Shanghai University (Natural*  
35 *Science)*, 2014, 20, 114-119.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60